
Healey ALS Platform Trial
Full Clinical Trial Name
Clinical Trial
- Neurology
Phase
Patient Type
Purpose
To evaluate the efficacy of multiple investigational medications (as compared to placebo) on ALS disease progression
Description
The Healey ALS Platform trial is a clinical trial that originated out of the Healey Center for ALS at Massachusetts General Hospital and is being conducted at several locations throughout the US, including Lehigh Valley Health Network. Through its unique and innovative design, the Healey ALS Platform Trial is a clinical study engineered to investigate multiple investigational drugs at one time, thereby providing more options for participants in the trial and allowing for faster scientific discovery.
Eligibility
- Participants must be diagnosed by a neurologist with ALS (also known as Lou Gehrig’s Disease)
- Participants must be age 18 years or older
- Onset of weakness due to ALS must be within the last 36 months (3 years)
- Participants must have the ability to swallow pills and liquids
- Participants cannot have a history of cancer or be actively treated for cancer
- Participants cannot have been exposed to any gene therapies for ALS treatment
- Participants cannot have any unstable psychiatric disease, cognitive impairment, dementia or substance abuse
To Participate
Please contact the Network Office of Research and Innovation at 610-402-9543.
Learn more about the full clinical trial
Full description at clinicaltrials.gov
For additional information
https://www.massgeneral.org/neurology/als/research/platform-trial
Doctor(s) running this study
